Print version | 
Send article | 
RSS feed
Xceleron sign an agreement with Biofrontera Bioscience GmbH to accelerate drug development using microdosing
19 Jul 2006 -
Xceleron, a service provider specialising in zeptoanalysis to accelerate drug development, announce an agreement for a Phase 0 microdose study with Biofrontera Bioscience GmbH, a member of the German Biofrontera Group, specializing in the development of drugs for the treatment of dermatological and inflammatory diseases. The study's purpose is to administer sub-pharmacological dose levels of promising drug candidates in human volunteers in order to gain critical pharmacokinetic information which in turn will enable the most promising drug candidate(s) to be progressed to Phase I trials.
Dr Reinhold Gahlmann, Managing Director of Biofrontera Bioscience GmbH, commented: "Our collaboration with Xceleron, and the use of their highly innovative approach, will save Biofrontera significant time and cost, allowing us to focus resources on our most promising preclinical drug candidates going forward".
Xceleron will co-ordinate the complete microdose project from synthesis through clinical trials (with Dutch clinical partners Pharma Bio-research) and finally zeptoanalysis at the Company's GLP accredited laboratories in York, UK using ultra-sensitive accelerator mass spectrometery (AMS) - the world's most sensitive measuring device that enables the microdosing concept.
"This agreement means that Biofrontera becomes Xceleron's 89th client and confirms that microdosing is fast becoming an accepted approach in drug development with the interface between preclinical and clinical trial stages radically changing" said Professor Colin Garner, Xceleron's CEO.
Top